Prodotti competitors / Area Kite
EU - Viracta's Nana-val granted ODD by EC in DLBCL
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Viracta has announced that the European Commission (EC) has granted an orphan drug designation (ODD) to its all-oral combination product candidate, Nana-val (nanatinostat and valganciclovir), for the treatment of diffuse large B-cell lymphoma (DLBCL). The EC previously granted ODD to Nana-val for the treatment of peripheral T-cell lymphoma.
As a reminder, Nana-val was previously granted ODD by the U.S. Food and Drug Administration for the treatment of T-cell lymphoma, post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and Epstein-Barr virus-positive (EBV+) DLBCL, not otherwise specified.
Reference link: Viracta press release
Grazie per il tuo feedback!